All patients should have access to the healthcare they deserve, regardless of who they are. To eliminate barriers to healthcare access, we’re fostering collaborations between expert organisations and underserved communities. By leading global partnerships for HIV treatment and vaccine awareness initiatives, we’re putting health equity at the forefront of what we do. Find out why closing the health equity gap is better for everyone 👇 https://gsk.to/3Bq24gC
Sobre nosotros
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Sitio web
-
http://www.gsk.com
Enlace externo para GSK
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- London, England
- Tipo
- Empresa pública
- Especialidades
- Pharmaceutical products y Vaccines
Ubicaciones
Empleados en GSK
Actualizaciones
-
“We had to rewire the organization, set it up for success, build our capabilities, and build our platforms” - our Chief Data and Technology Officer, Shobie Ramakrishnan, discusses how we're using data science and AI to reimagine what's possible for patients and society. Data and advanced tech are revolutionising how we discover, develop, and manufacture medicines and vaccines, with in-house capabilities driving progress and improving efficiencies across R&D, supply chains, and commercial operations. 🔗 Find out more in this article from Fortune: https://gsk.to/3BtP2Pf
-
-
Did you know we’re in the middle of a global outbreak of whooping cough? Thankfully, it is vaccine-preventable and would be less widespread were it not for the steady reduction in vaccine uptake we are seeing across the life course. In this article, Susie Barnes – SVP, Global Medical Affairs, Vaccines at GSK – explains why immunisation is one of the most cost-effective interventions available, and how, through ongoing prevention, we can protect ourselves throughout our lives. Read it here 👇 https://gsk.to/3DnXO1v
-
-
There are more than 200 different viruses that can cause colds. However, they rarely have serious consequences and people tend to get better on their own – usually between a week to 10 days. The trouble is the symptoms of the common cold can be similar to other potentially more serious respiratory infections that may require hospital treatment. This category of infections includes influenza, or flu, COVID-19 and respiratory syncytial virus, or RSV. So how can we tell the difference? Take a look at our symptoms checker below 👇 And read our new Behind the Science article to find out more: https://gsk.to/4glehSU
-
-
For #Investors: At the Meet the Management event, our leaders will discuss the next wave of R&D at GSK - showing how our deep expertise in immune science, advanced technologies and world-class strategic partnerships are paving the way for new and better innovation to deliver growth at scale to 2030 and beyond.
-
#News for #Investors and #Media: Today, we are pleased to share that the FDA granted Breakthrough Therapy Designation to one of our immuno-oncology treatments. Learn more: https://gsk.to/3ZTngop
-
#News for #Investors and #Media: Today, we announced that the European Medicines Agency has granted Priority Medicines (PRIME) Designation for an investigational antibody-drug conjugate in our oncology pipeline. Learn more: https://gsk.to/3ZRT6lA
-
#News for #Investors and #Media: Today, we announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending an expanded indication of our immuno-oncology cancer therapy in the EU. Learn more: https://gsk.to/3P4dbid
-
Pertussis, or ‘whooping cough’, is a highly infectious, vaccine preventable disease. It can affect anyone, though the risk of hospitalisation is highest for infants, people with respiratory conditions like COPD and asthma, and adults over 65. Right now, we’re in the middle of a global outbreak, with several countries – including the UK – recording higher numbers of cases than they’ve seen in years. This means the chance of a newborn, a young child, or a chronically ill person becoming infected with the disease is far greater, and a rise in pertussis-related deaths could become more likely. So how did we get here? And how do we protect ourselves in the future? Read our new Behind the Science article by Susie Barnes, SVP of Vaccines at GSK, to find out: https://gsk.to/3D9cEZZ
-
-
With #ASH24 now wrapped up, we return to our offices and laboratories energised by our discussions and insights from leaders in the oncology community. As cancer research advances, we are focused on delivering potentially transformative care for patients living with difficult-to-treat blood cancers. Learn more: https://gsk.me/41AQUQH
-